Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“For the years ended December 31, 2025, 2024 and 2023 , AnovoRx product sales represented 84.6 %, 93.6 % and 78.2 % of net revenues, respectively.”
$68M relationship
basisETON fy2025 · closed 2025-12 $80M
FILING10-K0001437749-26-009059cik 0001710340
“Net revenue of $31.6 million in 2023 included $5.5 million of licensing revenue from the sale of our neurology product royalty streams to Azurity in June 2023.”
$14M relationship
basisETON fy2025 · closed 2025-12 $80M
FILING10-K0001437749-26-009059
“In December 2024, the Company acquired GALZIN® (zinc acetate) from Teva Pharmaceuticals USA, Inc and assumed the commercialization of the product in the U.S. during March of 2025.”
FILING10-K0001437749-26-009059cik 0001710340
“On October 2, 2024, the Company and Ipsen Biopharmaceuticals, Inc. ("Ipsen"), a subsidiary of Ipsen S.A., entered into an Asset Purchase Agreement (the "Purchase Agreement"), whereby the Company agreed to acquire Increlex® (mecasermin injection) from Ipsen.”
FILING10-K0001437749-26-009059cik 0001710340
“In November 2024, the Company entered into a licensing agreement with AMMTeK. pursuant to which the Company has agreed to acquire the U.S. rights to Amglidia (glyburide oral suspension).”
FILING10-K0001437749-26-009059cik 0001710340
“In June 2021, the Company acquired U.S. and Canadian rights to Crossject's ZENEO® hydrocortisone needleless autoinjector, which is under development as a rescue treatment for adrenal crisis.”
FILING10-K0001437749-26-009059cik 0001710340
“In March 2020, the Company entered into an Exclusive License and Supply Agreement (the "Alkindi License Agreement") with Diurnal for marketing ALKINDI SPRINKLE® in the United States.”
FILING10-K0001437749-26-009059cik 0001710340
“In February 2026, the Company entered into a license agreement with Pierre Fabre Medicament Sas ("Pierre Fabre") for the exclusive rights to Hemangeol®, a product used for the treatment of proliferating infantile hermangioma.”
FILING10-K0001437749-26-009059cik 0001710340
“In March 2024, the Company acquired the U.S. rights to PKU GOLIKE® from Relief Therapeutics Holding SA.”
FILING10-K0001437749-26-009059cik 0001710340
“In March 2023, the Company acquired rare disease endocrinology product candidate ET- 600 from Tulex.”
FILING10-K0001437749-26-009059cik 0001710340
“In March 2025, the Company out-licensed the commercial rights to INCRELEX® in territories outside of the U.S. to Esteve Pharmaceuticals, S.A. ("Esteve").”
FILING10-K0001437749-26-009059cik 0001710340
“The decrease in cash from financing activities during the twelve-months ended December 31, 2025 was primarily associated with net proceeds received from expanding our credit agreement with SWK Holdings Corporation ("SWK") and proceeds from common stock issued in a private placement offering in 2024.”
FILING10-K0001437749-26-009059cik 0001710340
“The Company's revenues and its accounts receivable balances are highly concentrated and consist of sales to and amounts due from AnovoRx and Optime Care for the Company's INCRELEX®, ALKINDI SPRINKLE®, KHINDIVI TM , GALZIN®, Carglumic Acid, Betaine Anhydrous and Nitisinone products, as well as from Pentec Health for sales of the Company's PKU GOLIKE® product.”
FILING10-K0001437749-26-009059cik 0001710340
“The Company's revenues and its accounts receivable balances are highly concentrated and consist of sales to and amounts due from AnovoRx and Optime Care for the Company's INCRELEX®, ALKINDI SPRINKLE®, KHINDIVI TM , GALZIN®, Carglumic Acid, Betaine Anhydrous and Nitisinone products, as well as from Pentec Health for sales of the Company's PKU GOLIKE® product.”
FILING10-K0001437749-26-009059cik 0001710340
Watchlist prices, news filtered to it, and its next report on your desk.
Eton Pharmaceuticals, Inc. has 9 disclosed suppliers and 5 disclosed customers. Each one is named in an SEC filing, either Eton Pharmaceuticals, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
Prev close 54.89 · gapped above the open, then crossed back over prior close. High/low 57.80 at 7:30 am ET, 54.36 at 3:30 pm ET.
Eton Pharmaceuticals, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
ETON (Eton Pharmaceuticals, Inc.) has 9 disclosed suppliers and 5 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: TEVA +0.76%, in healthcare.